Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 6, 2015, Pages 524-528

  Torii, Yasushi ^a,b   Goto, Yoshitaka ^a   Nakahira, Shinji ^a   Kozaki, Shunji ^c   Kaji, Ryuji ^d   Ginnaga, Akihiro ^a  

^a Kaketsuken   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Osaka Prefecture University   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A1; BOTULINUM TOXIN A2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; FEMALE; LD50; MOUSE; MUSCLE ACTION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION; ACTION POTENTIAL; ANIMAL; DRUG EFFECTS; HEMISPHERIC DOMINANCE; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAMUSCULAR DRUG ADMINISTRATION; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

MUS; RATTUS;

ACTION POTENTIALS; ANIMALS; BOTULINUM TOXINS, TYPE A; FEMALE; FUNCTIONAL LATERALITY; INJECTIONS, INTRAMUSCULAR; LETHAL DOSE 50; MICE; MICE, INBRED ICR; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928761883     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12351     Document Type: Article

References (24)

1. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-66.
2. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014;209:183-91.
3. Sakagichi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-94.
4. Jahn R, Niemann H. Molecular mechanisms of clostridial neurotoxins. Ann N Y Acad Sci 1994;733:245-55.
5. Sugii S, Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect Immun 1975;12:1262-70.
6. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-70.
7. Truong DD, Jost WH. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006;12:331-55.
8. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 2006;362:733-42.
9. Jacobson MJ, Lin G, Raphael B, Andreadis J, Johnson EA. Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol 2008;74:2778-86.
10. Dover N, Barash JR, Arnon SS. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J Clin Microbiol 2009;47:2349-50.
11. Dressler D. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007;29:1761-8.
12. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53:407-15.
13. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomized, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26-31.
14. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006;21:189-92.
15. Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009;301:2316.
16. Torii Y, Kiyota N, Sugimoto N, Mori Y, Goto Y, Harakawa T et al. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 2011;57:93-9.
17. Sakaguchi G, Ohishi I, Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. In: Lewis GE (ed.). Biomedical Aspects of Botulism. Academic Press, New York, NY, 1981;21-34.
18. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
19. Sakamoto T, Torii Y, Takahashi M, Ishida S, Goto Y, Nakano H et al. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats. Toxicon 2009;54:857-61.
20. Tang-Liu DD, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 2003;42:461-9.
21. Wiegand H, Erdmann G, Wellhöner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976;292:161-5.
22. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53:3-9.
23. Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, Goto Y et al. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J Pharmacol Sci 2011;117:275-85.
24. Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnnaga A et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 2013;591:1031-43.